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 Background on antimicrobial resistance (AMR)
 Main activities on animal health policies preventing and fighting 
antimicrobial resistance (AMR) through Intergovernmental standards 
and guidelines
 Focus on the OIE ad hoc Group on prioritisation of diseases for 







 +1 billion people by 2050
 Focus on developing 
countries
 Demand for animal protein, 
increase by more than 50% 
 Unprecedented movement 
of people and commodities
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http://news.discovery.com/history/archaeology/antibiotic-genes-found-in-mummy-151020.htm
Global leader for 
food and 
agriculture
Global leader for 
animal health and 
welfare standards




Joint priorities including Antimicrobial resistance (AMR)




 OIE and activates on preventing and fighting antimicrobial 
resistance (AMR)
 Focus on the OIE ad hoc Group on prioritisation of diseases for 
which vaccines could reduce antimicrobial use  in animals     
 Conclusion
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for Animal Health 
(OIE)
Creation of the 
United Nations
1924 20031945
OIE: an intergovernmental organisation founded 
in 1924 : 180 Member Countries in 2016 
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Codes and Manuals available on the OIE website
Terrestrial Manual - Purpose
 Describes internationally agreed standard 
laboratory methods for disease diagnosis
 Describes requirements for the production and 
control of vaccines and other biological products
 Available in full and up to date on line in English 




3.1 Laboratory methodologies for bacterial antimicrobial 
susceptibility testing
3.2 Biotechnology in the diagnosis of infectious diseases
3.3 The application of biotechnology to the development of 
veterinary vaccines
3.4 The role of official bodies in the international regulation of 
veterinary biologicals
3.5 Managing biorisk: examples of aligning risk management 
strategies with assessed biorisks
3.6 OIE Validation Guidelines
Terrestrial Manual – Part 3
12
OIE activities on preventing and fighting  AMR 
 Initiatives to improve good governance of veterinary 
services
 Global database on antimicrobials use in animals 
worldwide 
 Contributing to the availability of quality assured 
antimicrobials and their prudent and responsible use
 List of antibiotics of critical importance for animal health
 Ad hoc Group on AMR and ad hoc Group on prioritization of 
diseases for which vaccines could reduce AMR in animals
 2nd International Symposium on Alternatives to 
Antibiotics for Animal Production (USDA with the support 




 OIE and activates on preventing and fighting antimicrobial 
resistance (AMR)
 Focus on the OIE ad hoc Group on prioritisation of diseases for 
which vaccines could reduce antimicrobial use  in animals     
 Conclusion
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Purpose of the ad hoc Group
 “Provide guidance on prioritisation of disease for which 
the use of already available and new vaccines could 
reduce antimicrobial use in animals, focusing the first 
step on pigs, poultry and fish “
 Identify actions to improve utilisation of such vaccines
 To support the WHO Global Action Plan on AMR which 
makes provision for such approach
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Terms of Reference (ToR)
 Consider disease for which the availability and use of 
appropriate vaccines could reduce antimicrobial use in 
animals 
 Rank bacterial disease in terrestrial (pig and poultry) and 
aquatic (fish) animals by animal group, which cause the 
highest use of antimicrobials in the animal concerned  
 Refine the ranking by considering relevant factors 
impacting vaccine development, effectiveness or 
implementation of vaccination  
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Methodology
 Development of a template and guiding criteria for the 
ranking of diseases:
• For the purpose of stimulating research into new or 
better adopted vaccines with the aim of reducing the 
use of antibiotics 
• The development of multivalent vaccines should 
potentially cover a broad range of issues and 




Proposed chicken, swine and fish diseases where development or improvement of 
vaccines would have a high impact on antibiotic use :
Key principles: 
1. Identification of the most prevalent and important bacterial infections in chickens, 
swine, and identification of fish species that are commonly farmed and associated with 
high antibiotic use, and associated prevalent bacterial infections in those species. 
2. Identification of common non-bacterial infections in chicken, swine and fish (e.g. 
protozoal, viral) showing clinical signs that trigger empirical antibiotic treatment (e.g. 
for diarrhoea) and which also result frequently in bacterial co-infection.
3. An assessment of antibiotic use in response to the syndromic indication or diagnosed 
disease. This was categorised as high, medium or low in the context of considered 
use compared with the total use of antibiotics in that animal species.
4. The availability of a vaccine(s), and if available, their effectiveness.
5. The potential for a new or improved vaccine to reduce the need for antibiotic treatment
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Tables: Infections for which new or improved vaccines 
would significantly reduce the need for antibiotic use 








Major constraints to 


















Escherichia coli  
(Yolk sac infection, airsacculitis, 
cellulitis) 
High Yes  Omphalitis: secondary bacterial infection 
– not a disease one can immunize 
against 
 Strain coverage limited 
 Airsacculitis, cellulitis: vaccines available, 
e.g. live aerosol vaccine. However, 
Serotype coverage limited and field 
efficay variable 
High 
Infectious Bursal Disease virus 
(secondary bacterial infections) 
Medium Yes   Issues with vaccine application 
 Short window of opportunity to vaccinate 






(airsacculitis, cellulitis, salpingitis 
and peritonitis) 





Clostridium perfringens, type A 
(necrotic enteritis) 
High Yes   Toxoid vaccine for layers providing only 
short-lasting passive immunity 
 Research needed to achieve active 
immunity. 
 Improved and/or more convenient (mass 
vaccination) vaccine needed for broilers 
High 
Coccidiosis 
(secondary bacterial infections) 
High Yes   Lack of cross-protection 
 Strains must be matched to infectious 
agent 
 Current vaccines are not attenuated and 
can produce low dose infection 
 Sub-unit vaccines have not been 
successful 
High 
Infectious Bronchitis virus 
(secondary bacterial infections) 
Medium Yes  Issues with strain matching and strain 
coverage 
 High mutation rate of virus 
Medium 
 
Table 1: Infections for which new or improved vaccines would significantly 
reduce the need for antibiotic use in chickens
* does not cover autogenous vaccines
Report of the meeting of the OIE ad hoc Group on 
Prioritisation of Diseases for which Vaccines could 
Reduce Antimicrobial Use in Animals
Poultry diseases
 Escherichia coli (Yolk sac infection, airsacculitis, cellulitis) (H)
 Clostridium perfringens, type A (necrotic enteritis) (H)
 Coccidiosis (secondary bacterial infections) (H)
 Infectious bronchitis virus (secondary bacterial infections) (H)















Streptococcus suis High Yes  Strain coverage too narrow  
 Lack of cross-protection 
 Poor immunogenicity due to being a capsule 
based vaccine 
High 
Haemophilus parasuis Medium Yes  Serotype specific with variable cross-
protection 
 Maternal antibody interference 
Medium 
Respiratory Pasteurella multocida (for 
pneumonic disease) 
High No  No vaccine with approved label claim for 
pneumonia  
 (There is a vaccine for atrophic rhinitis) 
High 
Mycoplasma hyopneumoniae High Yes  Does not completely prevent lung lesions 
 Animals continue to shed pathogen 




High Yes  Limited coverage 
 Good immunity only if serotype specific 
 Sub-unit vaccine which affords cross-
protection 
High 
Porcine Reproductive and 
Respiratory Syndrome virus 
(secondary bacterial infections) 
High Yes  Strain coverage limited 
 High virus mutation rate 
 Modest cross-protection 
 Vaccine evasion 
High 
Swine Influenza Virus 
(secondary bacterial infections) 
High Yes  Strain matching 
 Vaccine-associated enhanced respiratory 
disease (VAERD) 
 Lack of cross-protection 
 Efficacy in piglets limited 
High 
Enteric – neonatal Escherichia coli High for the 
syndrome, 
Low for E. coli 
Yes  Maternal vaccine provides effective 
lactogenic immunity 
 Coverage of enterotoxigenic E. coli may 




Escherichia coli High Yes  Maternal antibody interference 
 Short window for induction of immunity 
High 
Lawsonia intracellularis High Yes  Other pathogens in the syndrome 
(Brachyspira) not included 
 Antibiotic-free window for vaccination 
required (live attenuated oral vaccine) 
Low 
(see also  
Brachyspira) 
Brachyspira spp  
B. hyodysenteriae,  
B. pilosicoli 
Medium-high No  Low current research investment as changes 
in husbandry largely eliminated the disease 




High Yes  Reasons limiting wider adoption unknown High 
 
Table 2: Infections for which new or improved vaccines would significantly 
reduce the need for antibiotic use in swine
Swine diseases
 Streptococcus suis (H)
 Pasteurella multocida (for pneumonic disease) (H)
 Actinobacillus pleuropneumoniae (H)
 Porcine reproductive and respiratory syndrome virus (H)
 Swine influenza virus (H)
 E. coli (H)
 Brachyspira spp. including B. hyodysenteriae and B. pilosicoli (H)
 Rotaviruses (secondary bacterial infections) (H)
 Haemophilus parasuis (M)
















Aeromonas hydrophila and 
other species 







Pseudomonas spp.  High No  Disease is caused by a range of 
species and wide range of strains and 
serotypes 
High 






Aeromonas hydrophila and 
other species 
Medium No  Disease is caused by a range of 
species and wide range of strains and 
serotypes 




Streptococcus inae,  
S. agalactiae 
Medium Yes  Industry awareness of need is low (first 










Vibrio anguillarum  
Medium Yes  
(multivalent, 
injectable) 







Piscirickettsia salmonis Medium Yes  Multivalent vaccine which provides low 
protection for P. salmonis compared to 




introduction of an 
oral monovalent 
vaccine booster 
may improve the 
level of protection 






Medium Yes  Disease is caused by a wide range of 
serotypes 
 Industry awareness is low in some 
countries 
High  
Streptococcus spp. Medium Yes  Disease is caused by a wide range of 
serotypes 




Systemic Edwardsiella ictaluri,  
E. tarda 
Medium Yes  
(for Channel 
catfish) 
 Vaccines are not available for African 
catfish (an important farmed species) 
 Vaccines have very recently become 
available for Tra catfish and yet to be 
adopted by the industry 
High   
(for African catfish) 
Systemic Aeromonas hydrophila and 
other species 




Table 3: Infections for which new or improved vaccines would significantly 
reduce the need for antibiotic use in fish
Report of the meeting (contd)
Fish diseases
 Aeromonas hydrophila and other species (Freshwater cyprinids) (H)
 Pseudomonas spp. (Freshwater cyprinids) (H)
 Vibrio spp., (Marine fish) (H)
 Photobacterium spp. (Marine fish) (H)
 Streptococcus spp. (Marine fish) (H)
 Edwardsiella ictaluri, E. tarda (Catfish) (H)
 A. hydrophila and other species (Catfish) (H)
 Streptococcus inae, and S. agalactiae (Freshwater cichlids) (M)
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Outcome 
 In vaccine research could have a significant impact, 
particularly if it addressed the following four priority gaps:
• Maternal antibody interference
• Cross-protection or inclusion of relevant strains in vaccine 
formulations
• Occurrence of immunological interference in multivalent 
vaccines
• Innovative delivery systems to enable mass-vaccination
26
CONCLUSION 
 A  global vaccine research network should  be created to pull 
resources and expertise to address gaps for each of the priority 
diseases listed in Table 1-3. (Annex 5 of the Scientific Commission 
Report) 
 Call for encouragement for development for new technologies and 
handle the major shift on how vaccine discovery research may 
provide new opportunities for addressing the challenges
 Need to invest for new or improved vaccines  in order to reduce 
antibiotic use in the animals (as presented in details in the report 
and  tables).




Information is available at the OIE website









12 rue de Prony, 75017 Paris, France - www.oie.int – oie@oie.int
THANK YOU FOR YOUR 
ATTENTION ! 
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